Multiple Sclerosis Library

Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment.

150 150 NZ Stem Cell Treatment Centre

Autoimmune Dis. 2010 Dec 15;2011:164608. Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Witherick J, Wilkins A, Scolding N, Kemp K. Multiple Sclerosis and Stem Cell Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol BS16 1LE, UK. Abstract Although significant advances have recently been…

read more

Why should mesenchymal stem cells (MSCs) cure autoimmune diseases?

150 150 NZ Stem Cell Treatment Centre

Curr Opin Immunol. 2010 Dec;22(6):768-74. Epub 2010 Nov 17. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? Uccelli A, Prockop DJ. Department of Neurosciences Ophthalmology and Genetics, University of Genoa, Italy. auccelli@neurologia.unige.it Abstract The adult stem/progenitor cells from bone marrow and other tissues referred to as mesenchymal stem cells or multipotent mesenchymal stromal cells…

read more

Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells.

150 150 NZ Stem Cell Treatment Centre

Stem Cell Rev. 2010 Dec; 6(4) : 548-59 Inflammatory cytokine induced regulation of superoxide dismutase 3 expression by human mesenchymal stem cells. Kemp K, Gray E, Mallam E, Scolding N, Wilkins A Abstract Increasing evidence suggests that bone marrow derived-mesenchymal stem cells (MSCs) have neuroprotective properties and a major mechanism of action is through their…

read more

A consensus statement addressing mesenchymal stem cell transplantation for multiple sclerosis: it’s time!

150 150 NZ Stem Cell Treatment Centre

2010 Dec;6(4):500-6. A consensus statement addressing mesenchymal stem cell transplantation for multiple sclerosis: it’s time! Siatskas C, Payne NL, Short MA, Bernard CC. Monash immunology and stem cell laboratories, Monash University, Clayton, Victoria, 3800, Australia. christopher.siatskas@monash.edu Abstract Multiple sclerosis is a neurodegenerative disease of the central nervous system that is characterized by inflammation, demyelination with…

read more

Stem cells as therapeutics for neurodegenerative disorders?

150 150 NZ Stem Cell Treatment Centre

Stem cells as therapeutics for neurodegenerative disorders? Mattson MP. Laboratory of Neurosciences, National Institute on Aging GRC 4F01, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA. mattsonm@grc.nia.nih.gov Abstract Aging is associated with a progressive increase in the risk of several prominent neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, stroke and amyotrophic lateral sclerosis.…

read more

Mesenchymal Stem Cells for Multiple Sclerosis: Does Neural Differentiation Really Matter?

150 150 NZ Stem Cell Treatment Centre

Curr Stem Cell Res Ther. 2010 Oct 18. [Epub ahead of print] Mesenchymal Stem Cells for Multiple Sclerosis: Does Neural Differentiation Really Matter? Uccelli A, Morando S, Bonanno S, Bonanni I, Leonardi A, Mancardi G. Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa. auccelli@neurologia.unige.it Abstract The lack of therapies fostering remyelination and regeneration…

read more

Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.

150 150 NZ Stem Cell Treatment Centre

J Neuroimmunol. 2010 Oct 8; 227(1-2) : 185-9. Epub 2010 Aug 21. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study. Yamout B, Hourani R, Salti H, Barada W, El-Hajj T, Al-Kutoubi A, Herlopian A, Baz EK, Mahfouz R, Khalil-Hamdan R, Kreidieh NM, El-Sabban M, Bazarbachi A. Departments of Internal…

read more

Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.

150 150 NZ Stem Cell Treatment Centre

Ann Hematol. 2010 Sep 25; Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Xu J, Ji BX, Su L, Dong HQ, Sun WL, Wan SG, Liu YO, Zhang P, Liu CY Abstract To evaluate clinical outcomes of autologous peripheral blood…

read more

The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood derived stem cells.

150 150 NZ Stem Cell Treatment Centre

Cell Transplant. 2010 Sep 30. doi: 10.3727/096368910X532855. The treatment of neurodegenerative disorders using umbilical cord blood and menstrual blood derived stem cells. Sanberg PR, Eve DJ, Willing AE, Garbuzova-Davis S, Tan J, Sanberg CD, Allickson JG, Cruz LE, Borlongan CV. Center Of Excellence for Aging and Brain Repair, Dept. Neurosurgery and Brain Reapir, University of…

read more

Hematopoietic SCT for the treatment of multiple sclerosis.

150 150 NZ Stem Cell Treatment Centre

Bone Marrow Transplant. 2010 Aug 9; Hematopoietic SCT for the treatment of multiple sclerosis. Atkins H Abstract Multiple sclerosis (MS) is the leading autoimmune indication for autologous hematopoietic SCT (aHSCT). Patient selection criteria and transplant interventions have been refined through a series of cohort and registry studies. High- and low-intensity chemotherapy-based conditioning regimens have been…

read more